Objective: To explore whether the isocitrate dehydrogenase 1 (IDH1) or 1p/19q status determines the prognostic vs predictive role of O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation in the Neuro-Oncology Working Group of the German Cancer Society (NOA)-04 trial anaplastic glioma biomarker cohort.
The predictive power of O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation for benefit from temozolomide (TMZ) as seen in glioblastoma 1, 2 was not detected in anaplastic glioma either in the Neuro-Oncology Working Group of the German Cancer Society (NOA)-04 trial 3 or in the anaplastic oligodendroglial tumor European Organisation for Research and Treatment of Cancer (EORTC) 26951 cohort. 4, 5 Here, MGMT promoter methylation was similarly prognostic for better outcome with both alkylating chemotherapy and radiotherapy (RT).
Among the explanations for these differences is a confounding influence of isocitrate dehydrogenase 1 (IDH1) mutations, which are associated with a glioma-CpG island methylator phenotype (GCIMP). 6 Mutations in IDH1 have been identified in approximately 60% to 80% of gliomas of World Health Organization (WHO) grades II and III and in secondary glioblastomas, but only in approximately 5% of primary glioblastomas. 7, 8 Patients with malignant gliomas carrying IDH1
mutations have a better outcome than patients with IDH1-wild-type gliomas, regardless of the specific treatment. 1, [8] [9] [10] [11] Primary glioblastomas without IDH1 mutation are biologically different. 12 Similarly, IDH1-wild-type low-grade and anaplastic gliomas are prognostically distinct from IDH1-mutated grade II/III gliomas. Importantly, the prognostic properties of all markers described so far become apparent only with any form of postoperative genotoxic treatment and do not signify the natural postoperative course of disease. 11, 13 The present analysis was performed to test the hypothesis that the IDH1 status (mutant vs wildtype) rather than histologic grading (WHO grade III vs IV) determines whether MGMT promoter methylation is prognostic for the benefit from either type of genotoxic therapy, RT or chemotherapy, or predictive specifically for benefit from alkylating agent chemotherapy.
METHODS Patients and evaluations. NOA-04 trial: Training cohort. The NOA-04 trial randomized adult patients with histologically confirmed WHO grade III anaplastic glioma to either RT (arm A) or alkylating chemotherapy (arms B/C). 3 Histologic diagnosis of anaplastic glioma was confirmed centrally at the Brain Tumor Reference Center in Bonn before study entry according to WHO classifications 1993 14 and 2000. 15 Median follow-up time was 54 months.
German Glioma Network validation cohort. The German Glioma Network (GGN) is a prospective cohort study that enrolled 2,549 newly diagnosed patients with various types of glioma and frozen tissue asservation from October 2004 to October 2010. From this cohort, we identified 363 patients with a diagnosis of primary anaplastic astrocytoma (n 5 75) or glioblastoma (n 5 288) confirmed by history-taking and central pathology review, 16 as well as adequate follow-up at least until progression, who were treated with RT alone or alkylator-based chemo-or radiochemotherapy. Two hundred thirty-nine patients were included in previous publications. 11, 17 Clinical data were prospectively documented on case report forms and centrally assembled as outlined before (http://www.gliomnetzwerk.de). 11 The patients were not commonly enrolled into clinical trials, and treatment decisions were made by the treating physicians, patients, and their families, without awareness of results of molecular parameters. Progression was defined locally at standardized clinical and MRI examinations 18 and not centrally reviewed. All patients gave written informed consent. The review boards of the participating institutions approved all activities of the GGN.
NOA-08 anaplastic astrocytoma biomarker validation cohort. The NOA-08 trial randomized elderly patients with malignant astrocytoma to primary RT or TMZ between 2005 and 2009. 19 Patients from this trial with anaplastic astrocytoma as well as information on MGMT 19 and IDH1 status (table 1) were pooled with the anaplastic glioma cohort of the GGN.
Molecular evaluations. For subpopulations from the NOA-04
and NOA-08 trials as well as the GGN cohort, for which biomaterial was available, MGMT promoter methylation (methylation-specific PCR), 1p/19q codeletions (fluorescence in situ hybridization) and IDH mutations (immunohistochemistry for IDH1 and sequencing for IDH1/2) status were assessed according to routine methods. 3, 11 The NOA-04 subgroup reported here was representative for the per protocol population of the trial (table e-1 on the Neurology ® Web site at www.neurology.org).
Standard protocol approvals, registrations, and patient consents. The NOA-04 trial (NCT00717210) was approved by the central ethics committee at the University of Tübingen (106/99) and all 39 partner sites and enrolled patients after written informed consent, which included molecular analyses performed with study data and materials.
Statistical analyses. The primary endpoint of NOA-04 was time from surgery to treatment failure stratified for therapy in the intention-to-treat population. Treatment failure was defined as withdrawal from therapy before progression after chemotherapy and RT in either sequence because of toxicity or poor clinical condition, progression after chemotherapy and RT in either sequence, or death. 3 Secondary endpoints included progression-free survival (PFS), overall survival, and clinical efficacy endpoints (time from surgery to treatment failure, PFS, and overall survival) stratified for histology, 1p/19q codeletion, MGMT promoter methylation, and IDH1 mutation status.
Tests used for homogeneity in the NOA-04 biomarker cohort were for age and Karnofsky Performance Score: Wilcoxon test; for all other variables: Fisher exact test. Missing values were excluded from the statistical tests. Here, we focused our analysis on PFS because differentiation between prediction and prognosis was the primary aim of the present post hoc analysis. Univariate analysis of PFS used Kaplan-Meier estimates. 20 Multivariate analysis used a Cox proportional hazards model fitted to adjust for confounding variables. Hazard ratios with 95% confidence intervals were estimated. The analysis was done in 2 steps. In the first step, we used the cohort of the NOA-04 trial to generate hypotheses concerning the role of MGMT promoter methylation and IDH1 mutation status as possible prognostic or predictive factors for PFS. In the second step, we aimed at confirming these hypotheses in the independent GGN/NOA-08 cohort. Analyses for interaction between IDH1 or 1p/19q and MGMT status for PFS were done using the Statistical Analyzing Program SAS 9.1.3 (SAS Institute, Cary, NC) and IBM SPSS Statistics Release 20.0.0 (IBM Corp., Armonk, NY).
RESULTS Information on MGMT and IDH1 status was available for 183 NOA-04 patients who comprised a training cohort. This subgroup was comparable to the group of 91 patients without MGMT and IDH1 status data available concerning the distribution of type of primary surgery, histology, age, and therapy group. The distribution to the RT arm and to the chemotherapy arms regarding baseline characteristics was balanced (table 1) . Baseline data for the GGN/NOA-08 pooled anaplastic astrocytoma cohort used as a validation cohort commonly treated with RT alone (n 5 42) or chemotherapy 6 RT (n 5 67) are also provided in table 1.
In the NOA-04 cohort, PFS was overall longer in patients with IDH1-mutant tumors than in patients with IDH1-wild-type tumors (41.6 vs 15.2 months, p , 0.0001). Also, PFS was longer in patients with MGMT-methylated tumors compared with those with MGMT-unmethylated tumors (41.6 vs 16.9 months, p , 0.0001). To answer the question whether the prognostic or therapy modality-predictive impact of MGMT promoter methylation depends on the IDH1 status, we compared PFS in the 4 groups separated by treatment. Patients with IDH1-mutant tumors had a longer PFS when the MGMT promoter was methylated, both with RT or chemotherapy. In patients with IDH1-wild-type tumors treated with RT, PFS did not differ dependent on the MGMT status, but patients without MGMT promoter methylation had a dramatically worse PFS when treated with alkylating chemotherapy alone (table 2) . Interestingly, a therapy-specific association was neither found for the 1p/19q codeleted patients with (n 5 71) and without (n 5 7) IDH1 mutation nor the 1p/19q intact patients with (n 5 55) and without (n 5 49) IDH1 mutation (data not shown). There were no IDH2 mutations in the samples analyzed. For the time-to-treatment failure, which generally meant alkylating chemotherapy after failure of RT and RT after failure of chemotherapy, patients with wild-type IDH1 benefited from RT regardless of MGMT status, whereas patients with a methylated MGMT promoter showed a larger benefit from chemotherapy. Importantly, patients with IDH1-wildtype MGMT-methylated tumors, who initially received chemotherapy, retained their benefit and patients with IDH1-wild-type MGMT-methylated tumors, who initially received RT, showed a benefit matching their MGMT status (table e-2). Next, we performed a multivariate analysis, which included all the previously identified prognostic factors from univariate analysis of the NOA-04 trial in addition to MGMT and IDH1, namely, resection status (complete vs incomplete vs biopsy), histology (astrocytic vs oligodendroglial), and age. In the IDH-wild-type group, extent of resection, age, and histologic subtype were prognostic factors. Most importantly, there was an interaction between MGMT status and the therapy used; i.e., MGMT promoter methylation predicted benefit from chemotherapy. In contrast, in the IDH-mutated group, there was no interaction between MGMT status and therapy. Only histologic subtype remained as a prognostic factor ( figure 1, table 3 ). In both groups, there was no prognostic or predictive role for the 1p/19q status (data not shown).
As a next step, we looked at patients with anaplastic glioma from the GGN and NOA-08 20 cohorts to confirm our finding. The only prominent difference in baseline characteristics between the RT and the TMZ/RT group was age (table 1) . PFS data from this cohort were plotted separated by the use of alkylatorbased treatment (RT vs alkylator-based chemo-or radiochemotherapy) and IDH1 mutation as well as MGMT promoter methylation status. Patients with IDH1 mutation and MGMT promoter methylation had a surprisingly long PFS of .5 years for a group of older patients. The small number of patients with the combination of IDH1 mutation and absence of MGMT promoter methylation made formal comparison with the group of patients with IDH1 mutation and methylated MGMT promoter impossible ( figure  e-1, table 4 ). In contrast, in patients with IDH1-wildtype tumors, MGMT promoter methylation was not associated with longer PFS when patients were treated with RT alone (p 5 0.598), but linked to significantly longer PFS when alkylating chemotherapy was part of the treatment (p 5 0.018). Analysis for interaction between therapy and MGMT status in an analog Cox-regression model for this validation dataset demonstrated a significant interaction term for IDH1-wildtype tumors (p 5 0.039). However, after adjustment to relevant clinical parameters, the interaction was no longer significant.
Thus, similar to the anaplastic glioma population of the NOA-04 trial, MGMT promoter methylation was only associated with benefit from alkylator-based chemo-and radiochemotherapy (as compared with RT alone) in patients with IDH1-wild-type anaplastic gliomas (figure e-1) . Interestingly, these results are further supported by an analysis of patients with glioblastoma from the GGN cohort. There, a low number of IDH1-mutated tumors precludes meaningful conclusions for this patient group, but again, MGMT was predictive for the effect of alkylating chemotherapy in the IDH1-wild-type tumors (table e-3).
DISCUSSION Epigenetic silencing of the MGMT gene by promoter hypermethylation and the resulting compromise in DNA repair have been associated with longer survival in patients with glioblastoma who receive alkylating agents. 21, 22 In the EORTC 26981/ 22981/NCIC CE.3 glioblastoma trial providing evidence for the use of TMZ, patients with a hypermethylated MGMT promoter preferentially benefited from the addition of TMZ to RT. 1 Similarly, hypermethylation of the MGMT promoter was predictive for the response to alkylating agent-based (radio-) chemotherapy in elderly patients. In 233 patients with glioblastoma .70 years, patients with MGMT-methylated tumors had longer PFS when treated with RT plus chemotherapy or chemotherapy alone compared with patients treated with RT alone. Patients with MGMTunmethylated tumors appeared to derive no benefit from chemotherapy given as primary or salvage treatment. 2 These data were readily confirmed in the randomized NOA-08 trial, which resulted in a practice-changing call for routine MGMT testing in elderly patients with glioblastoma. 19 NOA-04 challenged the view of a predictive role for MGMT promoter hypermethylation in malignant glioma. 3 While NOA-04 confirmed the prognostic relevance of MGMT promoter methylation, it did not support the suggestion that MGMT promoter methylation is generally predictive for benefit from alkylating chemotherapy.
1 NOA-04 also showed a marked difference in PFS between patients with vs without MGMT promoter methylation who were treated with RT alone. This finding was supported by a reanalysis of the Table 2 Progression-free survival in the NOA-04 biomarker cohort EORTC 26951 trial of oligodendroglial anaplastic tumors, 5 in which also patients with RT only in the standard arm had a superior PFS, when the MGMT promoter was hypermethylated. Thus, in anaplastic gliomas, MGMT promoter methylation is a favorable prognostic marker independent of the type of therapy, i.e., radio-or chemotherapy. This pattern might be associated with the high incidence of other prognostically favorable molecular markers in these tumors, such as IDH1 mutation, 1p/19q codeletion, or yet to be identified novel aberrations. It was concluded that MGMT promoter hypermethylation in anaplastic gliomas may be regarded as i) a prognostic marker for good outcome in patients treated with RT or any type of genotoxic therapy, or ii) predictive for response to RT itself. 3, 23 The R132 mutations in the IDH1 gene represent the most recent and to date strongest positive outcome marker in anaplastic gliomas that will likely influence histopathologic grading as a subclassifier in the group of malignant gliomas as well as stratification in future trials on anaplastic gliomas and may lead to a better understanding of the differences between anaplastic glioma and glioblastoma. 17 Already the original publication on IDH1 mutations in glioblastomas had indicated that tumors carrying IDH1 mutations had a better prognosis than IDH1-wild-type tumors. 24 This has been confirmed across gliomas of WHO grades II-IV, including both astrocytic and oligodendroglial tumors. 3, 9, 19 In contrast, it has not been possible to link IDH1 mutations to better responsiveness to specific types of treatment, neither in glioblastoma 11 nor in anaplastic gliomas in the NOA-04 3 or the EORTC 26951 trial. 10 Moreover, in patients with low-grade gliomas, IDH1 mutations were linked to improved overall survival, but not to response to TMZ at progression after RT. 13 , 25 The frequency of IDH1 mutation is between Figure 1 Kaplan-Meier survival estimates in the NOA-04 biomarker cohort PFS is shown by IDH1 mutation status (mutated or wild-type) and MGMT promoter methylation status MGMT promoter methylated (MGMT1) or unmethylated (MGMT2) for RT-treated patients (blue lines) or chemotherapy-treated patients (red lines). In this cohort, 25 events were censored in the RT and 16 in the chemotherapy groups, respectively; vertical lines on the Kaplan-Meier curves indicate this. IDH 5 isocitrate dehydrogenase; MGMT 5 O 6 -methylguanine-DNA methyltransferase; NOA 5 Neuro-Oncology Working Group of the German Cancer Society; PFS 5 progression-free survival; RT 5 radiotherapy.
50% and 70% in WHO grade III, 5% and 10% in WHO grade IV gliomas of younger patients, and almost zero in elderly patients with glioblastoma. 7, 23 The present analysis from the NOA-04 trial suggests an interesting and simple interaction model to explain the discrepancy of the relevance of the MGMT status in WHO grade III and IV gliomas. According to our data, MGMT promoter methylation is prognostic for patients with IDH1-mutant WHO grade III gliomas. In contrast, in patients with IDH1-wild-type tumors, MGMT promoter methylation is predictive for benefit from alkylating chemotherapy ( figure 1, tables 2-4) . This finding not only provides a good explanation for a long-standing conflict that proposed a principal difference between WHO grade III and WHO grade IV tumors but also suggests the necessity of testing for both, IDH1 mutations and methylation status of the MGMT promoter. Patients with anaplastic gliomas carrying wild-type IDH1 and a hypermethylated MGMT promoter may not be adequately treated with RT alone, but should be considered candidates for alkylating chemotherapy with TMZ or procarbazine/CCNU/vincristine, or be treated within one of the current trials (e.g., CATNON) Table 4 Progression-free survival in the GGN anaplastic astrocytoma/NOA-08 cohort 3 In the present analysis of the biomarker cohort, the factor extent of resection was no longer prognostic in both arms, and age as well as histologic subtype were no longer prognostic in the RT arm of this biomarker subset of patients.
for combined radiochemotherapy with TMZ. IDH1 mutational status rather than the WHO grade may more precisely determine whether the MGMT promoter status is predictive for benefit from alkylating chemotherapy. Interestingly, a similar interaction was not found for 1p/19q and MGMT status, but the absence of a 1p/19q codeletion conferred a worse prognosis in RT-treated and chemotherapy-treated patients (data not shown). However, 1p/19q codeletion has been developed as a strong predictive biomarker by long-term analysis of the EORTC 26951 26 and Radiation Therapy Oncology Group (RTOG) 94-02 27 trials and therefore needs to be included in the biomarker panel, which is of immediate relevance for patients with anaplastic glioma.
The current analyses were limited by sample and event number to a 2-factor interaction term. This is mirroring the clinical situation, whereby IDH information will be available and the decision to test for MGMT and to make a treatment decision will follow. In addition to the limited sample sizes, the post hoc hypothesis-generating character of these data, and the limitations of the supporting dataset, the present analysis leaves some questions unanswered. What is the biological basis for the prognostic value of IDH1 mutations in patients treated with RT? Is there a patient cohort that should be treated with combined radiochemotherapy, or may chemotherapy alone be sufficient? Is there a differential role of these biomarkers in one of the histologic subgroups? The first question will most likely be answered in the near future in the context of the association between IDH1 mutations and the so-called GCIMP, where tumors with IDH1 mutations build a distinct subset of samples displaying concerted hypermethylation at a large number of loci. 28, 29 In a subgroup analysis of EORTC 26951, GCIMP status correlated with survival, MGMT promoter hypermethylation, 1p/19q codeletion, and IDH1 mutation status. GCIMP status strongly increased the predictive accuracy of survival in a model including known clinical prognostic factors such as age and performance score. 30 The strong association between GCIMP status and MGMT promoter methylation suggested that the MGMT promoter methylation status is part of a more general, prognostically favorable, genome-wide methylation profile, which most likely includes radiosensitivity makers. Discovery of these markers may help in identifying patients with anaplastic glioma who would benefit from RT and could further open opportunities for targeted manipulation of the underlying pathways. Despite evidence for a mere alkylator therapy-predictive role for MGMT status from 3 randomized trials with RT-only and alkylator-based arms, 1, 19, 31 there is also conflicting data from a large retrospective analysis of an MD Anderson cohort. In the latter analysis, there was some prognostic effect of MGMT status for patients with glioblastoma treated with RT alone. 32 The present data are meant to generate an interesting hypothesis and to challenge the way that we are dealing with biomarker information, not marker by marker as in the past and even presently in the EORTC 26951 27 and RTOG 94-02 28 publications, but by acknowledging the interaction of the data that we know of.
The present data from NOA-04, GGN, and NOA-08 will provoke a discussion on the standard-of-care arm, RT, in the IDH1-wild-type, MGMT promoter hypermethylated patients of the CATNON trial, as well as on the TMZ-alone arm in the halted CODEL trial for patients with unmethylated tumors despite the low frequency of 1p/19q codeleted/MGMT-unmethylated tumors. In these trials, the standard arm is RT and the role of TMZ in patients with anaplastic gliomas without 1p/19q codeletion (CATNON) or with the codeletion (CODEL) is investigated. Similarly, there will be a discussion on the standard-of-practise outside trials. Data from these trials may further validate the role of MGMT as a predictive biomarker in the IDH1-wild-type patient population. It may confirm that alkylating chemotherapy produces no benefit in patients with unmethylated, IDH1-wild-type tumors, but will provoke the question whether TMZ alone with deferred RT may be a sufficient treatment in patients with MGMT promoter methylated and IDH1-wild-type tumors. 
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